Editor's note

This article was originally published on 24 June 2014 as part of the VacZine Analytics ExpertREACT series. It is reproduced here for archival purposes. Market conditions, pipeline statuses and regulatory positions described reflect the state of knowledge at that date.

The Caribbean outbreak

Chikungunya (CHIK) - an RNA alphavirus transmitted by Aedes mosquitoes causing fever, headache and severe arthralgia that can persist for more than 12 months - made its first documented Americas appearance in December 2013. By June 2014, 19 Caribbean islands had reported local transmission, with the Pan American Health Organisation (PAHO) recording more than 170,000 suspected cases and 14 deaths across the Dominican Republic, Guadeloupe and Martinique predominantly.

US travellers returning from the Caribbean had brought imported cases to at least 12 US states, predominantly Florida. Although no autochthonous US transmission had been documented at the time of publication, this was considered highly probable given the widespread distribution of Aedes albopictus mosquitoes across the continental US - a vector shown capable of sustaining transmission in temperate European settings (north-east Italy 2007, south-east France 2010).

Caribbean Suspected Cases
170,000+

PAHO-reported suspected Chikungunya cases across 19 Caribbean islands as of June 2014

Vaccine development status

A live-attenuated CHIK vaccine developed by the US Army had been discontinued for operational reasons, though the technology had been transferred to five undisclosed manufacturers potentially capable of progressing it to clinical trials. A virus-like particle (VLP) vaccine from NIAID was available for licensing. Most promisingly, in November 2013 THEMIS (Austria) and Institut Pasteur began a Phase I trial with a recombinant measles VLP vaccine, which had recently reported positive preliminary data.

"Cyclical patterns and long intervals between outbreaks have historically dampened vaccine development efforts. Local transmission in Brazil or the continental US would transform the commercial calculus."

Why now matters

The cyclical nature of CHIK - with outbreaks followed by "silent phases" as herd immunity builds - has historically reduced sustained developer commitment. But the Caribbean outbreak's proximity to both Brazil (2014 FIFA World Cup and 2016 Olympics host) and the continental US represents a qualitative shift in perceived threat. If autochthonous transmission occurs in either location, the commercial and political imperative for vaccine development will intensify substantially.